References in periodicals archive ?
The three types of POD approaches (BMDe, BMDa, and SNCD) are illustrated in Figure 1.
BMDLs were compared to the SNCD (specifically, [SNCD.sub.1.0], [SNCD.sub.0.67], and [SNCD.sub.0.5]).
Reversal of symptoms and abnormal histology after a GFD for a suitable period of time would confirm a diagnosis of SNCD. Murch et al.
Thereafter, assessment of disease status is monitored by anti-tTG antibody titres, which presents a problem in patients with SNCD. Apart from symptom resolution and blood tests investigating micronutrient status, how else can SNCD patients be best monitored continues to remain an unanswered question.
Estudio descriptivo retrospectivo en el que se evaluaron las historias clinicas de los pacientes menores de 18 anos con diagnostico de SNCD o SNCR que recibieron rituximab y micofenolato: estos pacientes habian tenido poca respuesta a otros inmunosupresores recibidos previamente; prednisolona, ciclofosfamida, ciclosporina y micofenolato.
SNCD: aparicion de proteinuria en el rango nefrotico (mayor de 40 mg/[m.sup.2]/hora) durante la disminucion progresiva de los esteroides o en las dos semanas siguientes a la suspension del medicamento.
The SNCD process is geared to determine when significant changes occur within a network's organizational structure; perhaps more importantly, this process also seeks to identify what caused these changes.
There are many assumptions in the SNCD process that seem questionable, both as to effectiveness and as to acceptable levels of invasiveness.
For a UERSNCIP > TEL, the greater the ratio, the greater the uncertainty in the BMD at the TEL from extrapolation below the SNCD. In this case, the SNCD could serve as the POD, and the gap between the UERSNA) and the TEL could be bridged by an additional factor (analogous to the LOAEL-to-NOAEL factor) or linear extrapolation.
2011), we compared the SNCD with traditional PODs used in risk assessment [i.e., the benchmark dose (BMD) and the no observed adverse effect level (NOAEL)].
2011) we suggested that further development of the SNCD concept could involve the use of alternative target risks (e.g., based on public health considerations, as well as alternative low-dose extrapolation models), and we also pointed out that animal-to-human extrapolation may be regarded as a separate step after the SNCD-based POD has been established.
We introduce the SNCD as a new PoD, defined as the dose where the additional risk is equal to the "background noise" (the difference between the upper and lower bounds of the two-sided 90% confidence interval on absolute risk) or a specified fraction thereof.